Nephrotoxicity after PRRT with 177Lu-DOTA-Octreotate Abstract #1388

Introduction: Renal toxicity may occur after Peptide Receptor Radionuclide Therapy (PRRT). Risk factors have been identified for renal toxicity after 90Y based PRRT.
Aim(s): We investigated the renal function over time, the incidence of nephrotoxicity and associated risk factors after PRRT with 177Lu-DOTA0-Tyr3-Octreotate. Kidney dose was evaluated and compared to the accepted dose limits in external beam radiotherapy (EBRT) and 90Y-based PRRT.
Materials and methods: The incidence of renal toxicity (CTCAE v4.0) was evaluated in 323 patients and analysis of the annual loss of creatinine clearance (CLR) was done in 209 patients. Risk factors, including absorbed kidney dose, were analyzed with a non-linear mixed effect regression model.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Hendrik Bergsma

To read results and conclusion, please login ...

Further abstracts you may be interested in

#335 Dosimetry with 111In-octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC
Introduction: Kidneys are the critical organs in PRRT. A dosimetry protocol was implemented in an ongoing study to estimate the biological effective dose (BED) on the kidneys after 90Y-DOTATOC therapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Sofie M.D.A. Van Binnebeek
#698 Feasability of a Dosimetry Guided Therapy Planning for Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-Octreotate
Introduction: The efficacy and safety profile of PRRT can theoretically be optimized by planning each individual patient treatment on the absorbed dose to the critical organs and tumor lesions.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: PhD Mark W Konijnenberg
Keywords: PRRT, dosimetry
#2863 Introduction of Dosimetry on PRRT Practice. A Useful Tool to Detect Responders and Evaluate Treatment Safety
Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Federica Scalorbi
#2292 PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Wouter van der Zwan
#2996 A Head-to-Head Comparison between Two Software Packages for Hybrid Dosimetry after PRRT
Introduction: The number of dosimetry studies after PRRT is increasing, yet different methodologies are used which challenge comparison or pooling of results.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing